https://www.selleckchem.com/pr....oducts/bms-986158.ht
New (non-immunotherapeutic) treatment-strategies for AML/MDS-patients are under development. Dendritic cells (DCs) and 'leukemia-derived DC' (DCleu) connect the innate and the adaptive immunesystem and (re-)activate it, in their capacity as professional antigen-presenting cells (APCs). They can be generated ex vivo from peripheral blood mononuclear cells (PBMNCs) or whole blood (W, containing the -physiological-cellular/soluble microenvironment of individual patients using various DC/DCleu-generating methods or (for W minimalized
Like
Comment
Share
